Ventura R, Pascucci T, Catania M V, Musumeci S A, Puglisi-Allegra S
Dipartimento di Psicologia, University La Sapienza, Rome, Italy.
Behav Pharmacol. 2004 Sep;15(5-6):433-42. doi: 10.1097/00008877-200409000-00018.
Fragile X syndrome is an X-linked form of mental retardation including, among others, symptoms such as stereotypic behaviour, hyperactivity, hyperarousal, and cognitive deficits. We hypothesized that hyperactivity and/or compromised attentional, cognitive functions may lead to impaired performance in cognitive tasks in Fmr1 knockout mice, the most widely used animal model of fragile X syndrome, and suggested that psychostimulant treatment may improve performance by acting on one or both components. Since hyperactivity and cognitive functions have been suggested to depend on striatal and prefrontal cortex dopaminergic dysfunction, we assessed whether amphetamine produced beneficial, positive effects by acting on dopaminergic corticostriatal systems. Our results show that Fmr1 knockout mice are not able to discriminate between a familiar object and a novel one in the object recognition test, thus showing a clear-cut cognitive impairment that, to date, has been difficult to demonstrate in other cognitive tasks. Amphetamine improved performance of Fmr1 knockout mice, leading to enhanced ability to discriminate novel versus familiar objects, without significantly affecting locomotor activity. In agreement with behavioural data, amphetamine produced a greater increase in dopamine release in the prefrontal cortex of Fmr1 knockout compared with the wild-type mice, while a weak striatal dopaminergic response was observed in Fmr1 knockout mice. Our data support the view that the psychostimulant ameliorates performance in Fmr1 knockout mice by improving merely cognitive functions through its action on prefrontal cortical dopamine, irrespective of its action on motor hyperactivity. These results indicate that prefrontal cortical dopamine plays a major role in cognitive impairments characterizing Fmr1 knockout mice, thus pointing to an important aetiological factor in the fragile X syndrome.
脆性X综合征是一种X连锁的智力障碍形式,其症状包括刻板行为、多动、过度觉醒和认知缺陷等。我们推测,多动和/或受损的注意力、认知功能可能导致脆性X综合征最常用的动物模型——Fmr1基因敲除小鼠在认知任务中的表现受损,并提出精神兴奋剂治疗可能通过作用于其中一个或两个因素来改善表现。由于多动和认知功能被认为依赖于纹状体和前额叶皮质的多巴胺能功能障碍,我们评估了苯丙胺是否通过作用于多巴胺能皮质纹状体系统产生有益的积极影响。我们的结果表明,Fmr1基因敲除小鼠在物体识别测试中无法区分熟悉的物体和新物体,从而显示出明显的认知障碍,而这种障碍在其他认知任务中迄今为止难以证明。苯丙胺改善了Fmr1基因敲除小鼠的表现,使其区分新物体和熟悉物体的能力增强,而对运动活动没有显著影响。与行为数据一致,与野生型小鼠相比,苯丙胺使Fmr1基因敲除小鼠前额叶皮质中的多巴胺释放增加得更多,而在Fmr1基因敲除小鼠中观察到纹状体多巴胺能反应较弱。我们的数据支持这样一种观点,即精神兴奋剂通过作用于前额叶皮质多巴胺来改善Fmr1基因敲除小鼠的表现,仅改善认知功能,而不考虑其对运动多动方面的作用。这些结果表明,前额叶皮质多巴胺在Fmr1基因敲除小鼠的认知障碍中起主要作用,从而指出了脆性X综合征的一个重要病因因素。